Search for Clinical Trial Results

Sponsored By

Neurodermatitis - 9 Studies Found

Status Study
Completed Study Name: Study About Effectiveness of Silver-Containing Textiles for Treatment of Acute Neurodermatitis
Condition: Neurodermatitis
Date: 2005-09-12
Interventions:
  • Device: silver-contained textiles
  • Drug: co
Completed Study Name: Investigation of Efficacy and Safety of EPOGAM
Condition:
  • Atopic Dermatitis
  • Neurodermatitis

Date: 2009-04-08
Interventions: Drug: EPOGAM 1000 One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to
Not yet recruiting Study Name: Dapsone Prurigo Study
Condition: Lichen Simples Chronicus and Prurigo
Date: 2013-06-03
Interventions: Drug: Dapsone gel - verum Other Name: aczone gel
Completed Study Name: A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)
Condition: Prurigo Nodularis
Date: 2014-07-14
Interventions:
  • Drug: serlopitant NK1 receptor
Active, not recruiting Study Name: Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Condition:
  • Prurigo Nodularis
  • Nodularis Prurigo
  • Prurigo

Date: 2014-06-24
Interventions:
  • Drug: nalbuphine HCl ER 90 mg BID

Completed Study Name: Safety and Efficacy of CC-10004 for Prurigo Nodularis
Condition: Prurigo Nodularis
Date: 2009-03-23
Interventions: Drug: CC-10004 30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
Completed Study Name: Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis
Condition: Prurigo Nodularis
Date: 2007-09-19
Interventions: Drug: citalopram (cipralex) 10-20 mg/day, for 12 weeks.
Completed Study Name: Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Condition:
  • Prurigo Nodularis
  • Nodularis Prurigo
  • Prurigo
  • Date: 2014-06-24
    Interventions:
    • Drug: nalbuphine HCl ER tablets 90 mg BID

Completed Study Name: Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
Condition: Borderline Personality Disorder
Date: 2013-07-16
Interventions:
  • Drug: Selegiline The Study Dru